This observational study will evaluate the use in clinical practice and the efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer who have not received prior chemotherapy treatment in the metastatic setting. Patients for whom the treating physician has decided to initiate therapy with Avastin will be followed for 10 months.
Study Type
OBSERVATIONAL
Enrollment
27
Unnamed facility
Cape Town, South Africa
Unnamed facility
George, South Africa
Unnamed facility
Port Elizabeth, South Africa
Unnamed facility
Pretoria, South Africa
Unnamed facility
Vereeniging, South Africa
Dosage/schedule of 1st-line Avastin
Time frame: approximately 3 years
Duration of treatment
Time frame: approximately 3 years
Chemotherapy regimens used in clinical practice
Time frame: approximately 3 years
Clinical/demographic patient characteristics at baseline
Time frame: approximately 3 years
Progression-free survival
Time frame: approximately 3 years
Relationship between termination of Avastin treatment and time point of progression
Time frame: approximately 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.